Abbisko Cayman Limited (HK:2256) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbisko Cayman Limited has commenced a Phase II clinical trial for ABSK043, an innovative oral PD-L1 inhibitor, in combination with furmonertinib to treat advanced non-small cell lung cancer with EGFR mutations. This study aims to enhance anti-tumor efficacy, potentially marking a significant advancement in cancer treatment. Investors are advised to proceed cautiously with the company’s shares, as the success of the drug is not guaranteed.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.